84008
document
Comparison of the effects of terazosin and enalapril on laboratory stress testing blood pressure in patients with essential hypertension . It is the current opinion that an ideal antihypertensive drug should reduce blood pressure ( BP ) not only at rest but also during stressful situations . The current study was aimed to compare the effects of the selective alpha 1-adrenergic blocker terazosin ( 5 mg once daily ) and of the angiotensin-converting enzyme inhibitor enalapril ( 20 mg once daily ) on cardiovascular response to a set of standardized laboratory stressors , such as mental arithmetic , handgrip test and cycle ergometry , in a group of 16 essential hypertensive patients . The study was a randomized , double-blind , cross-over trial preceded by a placebo run-in period . Terazosin and enalapril had a comparable effect on resting BP , reducing systolic ( SBP ) and diastolic ( DBP ) blood pressure from 159.5 +/- 13.9/101.6 +/- 8.8 mm Hg during placebo by 7.8 % /6.7 % and by 11.3 % /10.2 % , respectively . The " response " rate to the two treatments was approximately the same , being 69 % and 75 % after terazosin and enalapril , respectively . During mental arithmetic , from an average of 181.6 +/- 17.8/118.6 +/- 11.5 mm Hg during placebo , BP was reduced by 11.5 % /7.9 % after terazosin and by 13.6 % /8.5 % after enalapril ; during handgrip test , BP decreased from 207.2 +/- 22.2/142.2 +/- 13.6 mm Hg by 7.3 % /8.4 % after terazosin and by 7.7 % /7.1 % after enalapril ; finally , during cycle ergometry , terazosin and enalapril lowered BP by 5.4 % /6.7 % and 7 % /3.1 % , respectively , from a placebo value of 215.5 +/- 17.3/127.6 +/- 11.2 . No significant difference in antihypertensive efficacy was observed between the two drugs , either at rest and during stress testing . ( ABSTRACT TRUNCATED AT 250 WORDS )
84009
Intervention_Pharmacological
terazosin
84010
Intervention_Pharmacological
enalapril
84011
Intervention_Pharmacological
antihypertensive drug
84012
Intervention_Pharmacological
selective alpha 1-adrenergic blocker terazosin
84013
Intervention_Pharmacological
angiotensin-converting enzyme inhibitor enalapril
84014
Intervention_Control
placebo
84015
Intervention_Pharmacological
Terazosin
84016
Intervention_Pharmacological
enalapril
84017
Intervention_Pharmacological
terazosin
84018
Intervention_Pharmacological
enalapril
84019
Intervention_Control
placebo
84020
Intervention_Pharmacological
terazosin
84021
Intervention_Pharmacological
enalapril
84022
Intervention_Pharmacological
terazosin
84023
Intervention_Pharmacological
enalapril
84024
Intervention_Control
placebo
84025
Outcome_Physical
resting BP , reducing systolic ( SBP ) and diastolic ( DBP ) blood pressure
84026
Outcome_Other
" response " rate
84027
Outcome_Physical
BP
84028
Outcome_Physical
BP
84029
Outcome_Physical
BP
84030
Participant_Condition
essential hypertension
84031
Participant_Sample-size
16